Expression of COX-2 on Reed-Sternberg cells is an independent unfavorable prognostic factor in Hodgkin lymphoma treated with ABVD

Early-Stage Hodgkin's Lymphoma

(2010) James O. Armitage   NEW ENGLAND JOURNAL OF MEDICINE

Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma

(2010) Christian Steidl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Does Rituximab Have a Place in Treating Classic Hodgkin Lymphoma?

(2010) Yasuhiro Oki et al.   Current Hematologic Malignancy Reports

Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma

(2009) Boris Böll et al.   BRITISH JOURNAL OF HAEMATOLOGY

Effects of the Anti-VEGF Monoclonal Antibody Bevacizumab in a Preclinical Model and in Patients With Refractory and Multiple Relapsed Hodgkin Lymphoma

(2009) Katrin S. Reiners et al.   JOURNAL OF IMMUNOTHERAPY

Cyclooxygenase-2 Up-Regulates Ataxia Telangiectasia and Rad3 Related through Extracellular Signal-Regulated Kinase Activation

(2009) Y. M. Kim et al.   MOLECULAR CANCER RESEARCH

Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: Tumor and microenvironment

(2008) Eric D. Hsi   LEUKEMIA & LYMPHOMA

Histological expression of angiogenic factors: VEGF, PDGFRα, and HIF-1α in Hodgkin lymphoma

(2008) Freda H. Passam et al.   PATHOLOGY RESEARCH AND PRACTICE

Treatment of Hodgkin lymphoma: the past, present and future

(2008) Andrew M Evens et al.   Nature clinical practice. Oncology